XML 21 R11.htm IDEA: XBRL DOCUMENT
v3.25.1

Product Revenues, Accounts Receivable, and Reserves for Product Sales | 3 Months Ended
--- | ---
Mar. 31, 2025
Product Revenues Accounts Receivable And Reserves For Product Sales [Abstract] |
Product Revenues, Accounts Receivable, and Reserves for Product Sales | 3. Product Revenues, Accounts Receivable, and Reserves for Product Sales The Company’s product revenues recorded in the United States, net of sales discounts, allowances and reserves, for the three months ended March 31, 2025 and 2024 were $149.9 million and $163.1 million, respectively. The Company’s product revenues consist of sales of EMPAVELI and SYFOVRE to specialty pharmacies and specialty distributors. The table reflects product revenue by major source for the following periods (in thousands):
|  | Three Months Ended March 31, |
|  | 2025 |  |  | 2024 |
Products: |  |  |  |  |  |
EMPAVELI |  | $ | 19,726 |  |  | $ | 25,610 |
SYFOVRE |  |  | 130,174 |  |  |  | 137,465 |
Total Product revenue, net |  | $ | 149,900 |  |  | $ | 163,075 |
The Company’s accounts receivable balance of $235.2 million as of March 31, 2025 and $264.9 million as of December 31, 2024, consisted of EMPAVELI and SYFOVRE product sales receivable and licensing and other revenue receivables from our collaboration with Sobi. The Company does not have a reserve related to expected credit losses against its accounts receivable balance and expects to collect its accounts receivable in the ordinary course of business. The Company’s product sales reserves totaled $38.9 million and $45.1 million as of March 31, 2025 and December 31, 2024, respectively. These amounts are included in accrued expenses on the Company’s unaudited condensed consolidated balance sheets. Th e following table summarizes activity in each of the product revenue allowance and reserve categories for the three months ended March 31, 2025 and 2024 (in thousands):
|  | Fees and patient assistance |  |  | Government and other rebates |  |  | Returns |  |  | Total |
Ending balance at December 31, 2024 |  | $ | 11,589 |  |  | $ | 31,533 |  |  | $ | 2,023 |  |  | $ | 45,145 |
Provision related to sales in the current year |  |  | 10,277 |  |  |  | 24,139 |  |  |  | 976 |  |  |  | 35,392 |
Adjustments related to prior period sales |  |  | 439 |  |  |  | (13 | ) |  |  | (382 | ) |  |  | 44 |
Credits and payments made |  |  | (13,084 | ) |  |  | (28,467 | ) |  |  | (126 | ) |  |  | (41,677 | )
Ending balance at March 31, 2025 |  | $ | 9,221 |  |  | $ | 27,192 |  |  | $ | 2,491 |  |  | $ | 38,904 |
|  | Fees and patient assistance |  |  | Government and other rebates |  |  | Returns |  |  | Total |
Ending balance at December 31, 2023 |  | $ | 5,674 |  |  | $ | 8,898 |  |  | $ | 2,053 |  |  | $ | 16,625 |
Provision related to sales in the current year |  |  | 9,575 |  |  |  | 13,125 |  |  |  | 1,355 |  |  |  | 24,055 |
Adjustments related to prior period sales |  |  | 146 |  |  |  | (19 | ) |  |  | (96 | ) |  |  | 31 |
Credits and payments made |  |  | (9,724 | ) |  |  | (9,906 | ) |  |  | (1,859 | ) |  |  | (21,489 | )
Ending balance at March 31, 2024 |  | $ | 5,671 |  |  | $ | 12,098 |  |  | $ | 1,453 |  |  | $ | 19,222 |
Significant customers - Gross product revenues and product sales receivable from the Company's customers who individually accounted for 10% of more of total gross product revenues and/or 10% or more of total product sales receivable consisted of the following:
|  | Percent of Total Gross Product Revenues
|  | Three Months Ended March 31,
|  | 2025 |  | 2024
Customer A |  | 11% |  | 15%
Customer C |  | 18% |  | 19%
Customer D |  | 58% |  | 59%
|  | Percent of Product Sales Receivable
|  | As of March 31,
|  | 2025 |  | 2024
Customer A |  | 4% |  | 3%
Customer C |  | 31% |  | 21%
Customer D |  | 49% |  | 67%
Factoring of accounts receivable and associated fees for the period ended March 31, 2025 and 2024 were as follows (in thousands):
|  | For the Three Months Ended March 31, |
|  | 2025 |  |  | 2024 |
Accounts receivable sold |  | $ | 99,735 |  |  | $ | — |
Less: factoring fees |  |  | (1,212 | ) |  |  | — |
Net cash proceeds |  | $ | 98,523 |  |  | $ | — |
The accounts receivable sold that remained outstanding as of March 31, 2025 and December 31, 2024 was $99.7 million and $86.1 million, respectively.

X
- Definition Product revenues, accounts receivable, and reserves for product sales. + References No definition available. + Details
Name: | apls_ProductRevenuesAccountsReceivableAndReservesForProductSalesAbstract
Namespace Prefix: | apls_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Product revenues, accounts receivable, and reserves for product sales. + References No definition available. + Details
Name: | apls_ProductRevenuesAccountsReceivableAndReservesForProductSalesTextBlock
Namespace Prefix: | apls_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration